Synaptogenix (SNPX) News Today → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Free SNPX Stock Alerts $4.53 +0.12 (+2.72%) (As of 05:27 PM ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineSynaptogenix, Inc.: Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingfinanznachrichten.de - April 24 at 5:25 PMSynaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listingprnewswire.com - April 24 at 9:15 AMSynaptogenix announces reverse stock split to regain Nasdaq complianceuk.investing.com - April 5 at 8:47 AMmarketbeat.com - April 5 at 6:02 AMWhat's Going On With Synaptogenix (SNPX) Stock?msn.com - April 4 at 5:46 PMSynaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listingfinance.yahoo.com - April 3 at 9:57 AMU.S. shares higher at close of trade; Dow Jones Industrial Average up 1.18%msn.com - February 22 at 8:39 PMSynaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disordersfinance.yahoo.com - December 19 at 2:36 PMSynaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer'sfinance.yahoo.com - December 6 at 2:15 PMSynaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technologyfinance.yahoo.com - November 2 at 11:29 AMSynaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Diseasefinance.yahoo.com - September 26 at 12:59 PMBryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Studyfinance.yahoo.com - September 7 at 10:07 AMSynaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosisprnewswire.com - July 19 at 9:02 AMShort Volatility Alert: Synaptogenix Incbenzinga.com - July 14 at 2:37 PMSynaptogenix Shares Halted On Circuit Breaker To The Upside, Stock Now Up 59.1%benzinga.com - July 13 at 1:58 PMSynaptogenix Shares Rise 48% After Alzheimer's Drug Abstract Accepted at Conferencemarketwatch.com - July 13 at 1:58 PMSynaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neurosciencefinance.yahoo.com - July 13 at 1:58 PMmarketbeat.com - July 13 at 10:12 AMSNPX - Synaptogenix, Inc.finance.yahoo.com - June 24 at 6:33 PMSynaptogenix Provides Corporate Update and Outlines Potential Business Opportunitiesfinance.yahoo.com - March 7 at 10:14 AMSNPX.Oreuters.com - February 27 at 12:25 AMPeering Into Synaptogenix's Recent Short Interestmsn.com - December 20 at 12:40 PMSynaptogenix crashes 69% as Phase 2 trial for Alzheimer’s candidate failsseekingalpha.com - December 16 at 1:26 PMSynaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Diseasefinance.yahoo.com - December 16 at 1:26 PMSynaptogenix: Bryostatin For Alzheimer's, As Binary As Can Beseekingalpha.com - December 9 at 4:55 PMSynaptogenix announces $15M private placement with existing investorsseekingalpha.com - November 18 at 2:36 PMSynaptogenix Announces $15 Million Private Placement with Existing Investorsfinance.yahoo.com - November 18 at 9:36 AMCompanies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growthca.finance.yahoo.com - October 22 at 11:28 AMSynaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022finance.yahoo.com - October 19 at 6:17 PMSynaptogenix Welcomes Lecanemab Phase 3 Trial Resultsfinance.yahoo.com - September 28 at 2:59 PMSYNAPTOGENIX, INC. : Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits (form 8-K) - Marketscreener.commarketscreener.com - August 17 at 3:07 AM2022-08-12 | NDAQ:SNPX | Press Release | Synaptogenix Inc. - Stockhousestockhouse.com - August 12 at 10:05 AMSynaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network - Yahoo Financefinance.yahoo.com - August 12 at 10:05 AMSynaptogenix Announces Live Ap - GuruFocus.comgurufocus.com - August 12 at 10:05 AMSynaptogenix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 - Marketscreener.commarketscreener.com - August 6 at 2:04 PMSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data - Yahoo Financefinance.yahoo.com - July 26 at 5:49 PMSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data - PR Newswireprnewswire.com - July 26 at 12:48 PMSynaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Datafinance.yahoo.com - July 26 at 12:48 PMRecap of Wednesday’s Biotech Catalysts - End of The Day Summary - Benzinga - Benzingabenzinga.com - July 20 at 10:59 PMSynaptogenix Advances Dosing Of First Patient In Dose Optimization Clinical Trial In Preparation For NIH- - Benzingabenzinga.com - July 20 at 12:58 PMSynaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data - PR Newswireprnewswire.com - July 20 at 12:58 PMSynaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Datafinance.yahoo.com - July 20 at 12:58 PMIROQUOIS CAPITAL NOMINATES SLA - GuruFocus.comgurufocus.com - July 13 at 10:45 AMSynaptogenix to Present at Sac - GuruFocus.comgurufocus.com - June 30 at 5:25 PMIROQUOIS CAPITAL NOMINATES SLATE OF HIGHLY QUALIFIED DIRECTOR CANDIDATES FOR ELECTION AT PHARMACYTE'S 2022 ANNUAL MEETING - Yahoo Financefinance.yahoo.com - June 23 at 9:39 AMSynaptogenix to Present at the Cell Symposium - GuruFocus.comgurufocus.com - June 16 at 3:29 PMmarketbeat.com - June 14 at 9:38 AMSynaptogenix to Present at the Cell Symposium - PR Newswireprnewswire.com - May 17 at 6:32 PMSynaptogenix to Present at the Cell Symposiumfinance.yahoo.com - May 17 at 6:32 PMSynaptogenix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 - Marketscreener.commarketscreener.com - May 14 at 3:46 PM Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address The Next Step of Their Control Is Here … (Ad)Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you. 4 simple steps to protect your privacy and money before it’s too late. SNPX Media Mentions By Week SNPX Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SNPX News Sentiment▼-0.330.32▲Average Medical News Sentiment SNPX News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SNPX Articles This Week▼30▲SNPX Articles Average Week Get Synaptogenix News Delivered to You Automatically Sign up to receive the latest news and ratings for SNPX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Bright Minds Biosciences News LumiraDx News GT Biopharma News China Pharma News Sonnet BioTherapeutics News Soligenix News PaxMedica News Kineta News Seelos Therapeutics News Petros Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SNPX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithMan Who Predicted 2008: “This Will be Worse.”AltimetryFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synaptogenix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
